Division of Experimental Oncology
You are hereDivision of Experimental Oncology > Group Rüegg > Publications > 2000-2004

Publications 2000-2004

2004 | 2003 | 2002 | 2001 | 2000
 

2004

C. Rüegg, O. Dormond, A. Mariotti. Endothelial cell integrins and COX-2 (2004) mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta. 2004 Mar 4;1654:51-67   PubMed

O. Dormond, L. Ponsonnet, M. Hasmim, A. Foletti and C. Rüegg. (2004) Manganese-induced integrin affinity maturation promotes recruitment of αVβ3 integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src. Thrombosis Hemost 92(1):151-61   PubMed

Zaric J, Ruegg C. Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation. J Biol Chem. 2004 Nov 3   PubMed

A. Broillet, J. Hantson, C. Rüegg, T. Messager, M. Schneider (2004) Assessment of microvascular perfusion changes in a rat breast tumor model usingSonoVue to monitor the effects of different anti-angiogenic therapies. Acad Radiol   PubMed

Doucey M.-A., Scapellino L., Zimmer J., Guillaume P., Luescher I., Bron C. and Held W. Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nature Immunology. 2004; 5(3):328-36   PubMed

TOP ^

2003

M.-A. Doucey, D. F. Legler, M. Faroudi, N. Bucheron, D. Naeher, D. Hudrisier, C. Rüegg, E. Palmer, L.-C. Cerottini, S. Valitutti, C. Bron and I. Luescher. (2003) Convergence of integrin and TCR/CD8-mediated signals is required for cytotoxic T lymphocyte activation. J. Biol. Chem. 278:26983-91   PubMed

C. Rüegg, R. Driscoll, P. Werffely-George and R. Stupp (2003) Translational research in tumor angiogenesis: from bench to bedside and back to the bench. Bulletin Suisse du Cancer, 23, 3-7

C. Rüegg and A. Mariotti (2003) Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Molec Life Sci. 60, 1135-1157   PubMed

O. Dormond and C Rüegg (2003) Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A. Thrombosis Hemostasis 90, 577-855   PubMed

C. Rüegg, J. Zaric, and R. Stupp (2003) Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality? Ann Med, 35, 486-497

M. Bezzi, M. Hasmim, G. Bieler, O. Dormond, and C. Rüegg (2003) Zoledronate sensitizes endothelial cells to Tumor Necrosis Factor-induced programmed cell death: evidence for the suppression of sustained activation of Focal Adhesion Kinase and Protein Kinase B/Akt J. Biol. Chem. (in press)   PubMed

L. Gagnoux-Palacios, M.Dans, W. van,t Hof, A. Mariotti, G. Meneguzzi, M. D. Resh and F. G. Giancotti (2003) Integrin alpha6beta4 signaling requires compartmentalization in lipid rafts J.Cell Biol. 162, 1189-1196   PubMed

C. Rüegg, R. Driscoll, P. Werffely-George, Jean-Yves Meuwly, Khalil Zaman and R. Stupp (2003) The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials Curr Mol Med

R. Stupp and C. Rüegg (2003) New drugs and combinations for malignant glioma FORUM Trends Exp Clinic Med,13, 60-75

Doucey M.-A., Goffin Laurence, Naeher Dieter., Michielin Olivier, Baumgärtner Petra, Guillaume Philippe, Palmer Ed.,. and Luescher I.F. CD3delta establishs a functional link between the T cell receptor and CD8. J. Biol. Chem. 2003, 278(5):3257-64   PubMed

Legler D.F., Micheau O., Doucey M.-A., Tschopp J.and Bron C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 2003, 18(5):655-64   PubMed

Guillaume P, Legler D.F., Boucheron N., Doucey M.-A., and Luescher I.F. Soluble MHC-peptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis. J. Biol. Chem. 2003, 278(7):4500-9   PubMed

TOP ^

2002

O. Dormond, F. Lejeune and C. Rüegg. (2002) Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and p27Kip1 expression in endothelial cells by TNF/IFN-γ. Anticancer Res., 22 (6), 3159-3164.   PubMed

O. Dormond, M. Bezzi A. Mariotti and C. Rüegg. (2002) Prostaglandin E2 promotes integrin αVβ3-mediated endothelial cell adhesion, Rac activation, and spreading through a cAMP/PKA-dependent effect. J. Biol. Chem. 277, 45838-45846   PubMed

C. Rüegg, (2002) Targeting the tumor vasculature as an anti-cancer therapy : emerging paradigms and open questions. Swiss Medical Forum, 14, 317-323

C. Rüegg, O. Dormond and A. Foletti. (2002) Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells : which side to hit ? Endothelium, 9, 151-160   PubMed

D. Hauzenberger, C. Rüegg and J. Klominek (2002). Role of Tenascin-C for inhibition of T cell adhesion, migration and activation. Landes Bioscience Publishers

Dutoit V., Rubio-Godoy V., Doucey M.-A., Batard P., Lienard D., Rimoldi D., Speiser D., Guillaume P., Cerottini J.-C., Romero P., Valmori D. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. Journal of Immunology. 2002, 168(3):1167-71   PubMed

TOP ^

2001

L. Leyton, P.Schneider, C. V. Labra, C. Rüegg, A. F.G. Quest and C. Bron (2001) Thy-1 binds to integrin β3 on astrocytes and triggers formation of focal contacts. Curr. Biol., 2001, 11:1028-1038. PubMed

O. Dormond, C. Paroz, and C. Rüegg (2001) Nonsteroidal anti-inflammatory drugs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial cell spreading, migration and angiogenesis. Nature Med, 9, 1041-1047. PubMed

M. D. Puente Navazo, D. Valmori and C. Rüegg (2001) The alternatively spliced domain TnFnIIIA1-A3 of Tenascin-C, an extracellular protein expressed in tumour stroma, suppresses T lymphocyte activation and secretion of TNF and IFN-γ. J. Immunol., 167, 6431-6440. PubMed

Mariotti A., Kedeshian P.A., Dans M., Curatola A.M., Gagnoux-Palacios L., and Giancotti F.G. (2001) EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. J. Cell Biol. 155, 447-458. PubMed

Dans M., Gagnoux-Palacios L., Blaikie P., Klein S., Mariotti A., and Giancotti F.G. (2001) Tyrosine phosphorylation of the β4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes. J. Biol. Chem. 276, 1494-1502. PubMed

C. Rüegg and O. Dormond (2001) Suppression of tumor angiogenesis by non steroidal anti inflammatory drugs: a new function for old drugs. The ScientificWorld ; 1, 808-811 PubMed

O. Dormond and C. Rüegg, (2001) Inhibition of tumor angiogenesis by non-steroidal anti inflammatory drugs : emerging mechanisms and therapeutic perspectives. Drug Res Updates, 4, 314-321. PubMed

Arnand, M., Ray, S., Doucey, M.-A., Weik, J., Ware, F. E., Hofsteenge, J., and Lehrman, M. Requirement of the Lec35 gene for all known classes of Monosaccharide-P-Dolichol dependent glycosyltransferases in mammals. Mol. Biol. Cell. 2001, 12(2):487-501 PubMed

B. Robert, P. Guillaume, I. Luescher, M.-A. Doucey, J.-C. Cerottini, P. Romero, and J.-P. Mach.. Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments. Cancer Immunity. 2001, 1:2(30) PubMed

Kalergis, A. M., Doucey, M.-A., Boucheron, N., Palmieri E., Goyarts, E. C., Vegh, Z., Luescher, I. F., Nathenson, S. G. Efficient T cell activation requires an optimal dwell time of interaction between the TCR and the peptide-MHC complex. Nature Immunology. 2001, 2(3):229-34 PubMed

Doucey, M.-A., Legler, D. F., Cerottini, J.-C., Bron, C., and Luescher, I. CTL activation is induced by cross-linking of TCR/MHC-peptide CD8/p56lck adducts in rafts. Eur. J. Immunol. 2001, 31(5):1561-70 PubMed

Doucey, M.-A., Legler, D. F., Cerottini, J.-C., Bron, C., and Luescher, I. Dipalmitoyl lipid blocks T cell activation by interfering with lipid raft signaling. FASEB J. 2001, 15(9):1601-3 PubMed

TOP ^

2000

M. Irmler, V. Steiner, C. Ruegg, H. Wajant, J. Tschopp (2000) Caspase-induced inactivation of the anti-apoptotic TRAF1 during Fas ligand-mediated apoptosis. FEBS Letters, 468, 129-133   PubMed

D. Oguey, P. Werfeli-George, and C. Rüegg (2000). Disruption of integrin-dependent adhesion and survival of endothelial cells by recombinant adenovirus expressing isolated β integrin cytoplasmic domains. Gene Therapy, 7, 1292-1303  PubMed

D. Hauzenberger, K. Hultenby, S. Sumitran, C. Ruegg and J. Klominek (2000) Induction of transendothelial migration in normal and malignant human T lymphocytes. Anticancer Res., 20, 2601-2611

C. Rüegg, O. Dormond, D. Oguey, F. Lejeune (2000) Results and perspectives on the clinical use of Tumor Necrosis Factor as anti-cancer agent and on its mechanisms of action. Drug Res Updates, 3, 271-276

C. Rüegg, O. Dormond, D. Oguey, F. Lejeune (2000) A decade in the clinical use of Tumor Necrosis Factor as anti-cancer agent: achievements and perspectives. Bulletin Suisse du Cancer, (4), 220-223

TOP ^

Search:
 Go
 
rss/atom
Chemin des Boveresses 155 - CH-1066 Epalinges  - Switzerland  -  Tel. +41 21 692 58 42  -  Fax +41 21 652 69 33
Swiss University